Solicitation from DEFENSE HEALTH AGENCY (DHA) • DEPT OF DEFENSE. Place of performance: TX. Response deadline: Apr 27, 2026. Industry: NAICS 325412 • PSC 6505.
As DoD CMMC rollout expands, approximately 80%+ of DoD solicitations are expected to include cybersecurity/CMMC requirements, including many non-tech scopes.
Awarded-market signal for NAICS 325412 (last 12 months), benchmarked to sector 32.
Navigate the lattice: hubs for browsing, trends for pricing signals.
SAM WDOL references matched to this opportunity's location and scope language.
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed:
a. Arynta - ADHD Agents - Stimulants
b. Atmeksi - Skeletal Muscle Relaxants and Comb - NA
c. Avtozma - TIBS - IL-1, IL-6, CTLA-4
d. Desmoda - Endocrine Agents Misc - NA
e. Foundayo - Metabolic Dysfunction A - Weight Loss A
f. Icotyde - TIBS -IL-23
g. Kygevvi - Metabolic Agents Misc - NA
h. Lerochol - Antilipidemics-1 - PCSK-9
i. Loargys - Metabolic Agents-Misc - Replacement Enzyme
j. Yuviwel - Growth Stimulating Agents - NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9203.
Pre-quotation teleconference is on April 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Files size/type shown when available.
A practical, capture-style breakdown of fit, requirements, risks, and next steps.
It summarizes awarded-contract behavior for the opportunity’s NAICS and sector, including a recent pricing band (P10–P90), momentum, and composition. Use it as context, not a guarantee.
The signal updates as new awarded notices enter the system. Always validate the official award and solicitation details on SAM.gov.
P10 is the 10th percentile award size and P90 is the 90th percentile. Together they describe the typical spread of award values.
